| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.TIBTECH.2006.07.005 |
| P698 | PubMed publication ID | 16876893 |
| P50 | author | Marc Cortese | Q55143871 |
| Vladimir N. Uversky | Q59698496 | ||
| P2093 | author name string | Pedro Romero | |
| A Keith Dunker | |||
| Christopher J Oldfield | |||
| Yugong Cheng | |||
| Ya-Yue J Van | |||
| Tanguy LeGall | |||
| James P Mueller | |||
| P2860 | cites work | BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. | Q33960826 |
| P433 | issue | 10 | |
| P921 | main subject | protein design | Q410814 |
| P304 | page(s) | 435-442 | |
| P577 | publication date | 2006-07-28 | |
| P1433 | published in | Trends in Biotechnology | Q2451465 |
| P1476 | title | Rational drug design via intrinsically disordered protein | |
| P478 | volume | 24 |
| Q37088664 | A careful disorderliness in the proteome: sites for interaction and targets for future therapies. |
| Q35642431 | A complex task? Direct modulation of transcription factors with small molecules |
| Q28681184 | A decade and a half of protein intrinsic disorder: biology still waits for physics |
| Q33331025 | A new protein linear motif benchmark for multiple sequence alignment software |
| Q37421771 | A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma |
| Q30358999 | Advantages of proteins being disordered. |
| Q41357989 | An Intriguing Correlation Based on the Superimposition of Residue Pairs with Inhibitors that Target Protein-Protein Interfaces |
| Q30377015 | An Overview of Practical Applications of Protein Disorder Prediction and Drive for Faster, More Accurate Predictions. |
| Q31122058 | An integrative in silico approach for discovering candidates for drug-targetable protein-protein interactions in interactome data |
| Q50979449 | Backbone and side-chain resonance assignments for the tmRNA-binding protein, SmpB, from Mycobacterium tuberculosis. |
| Q47900402 | Backbone conformational preferences of an intrinsically disordered protein in solution. |
| Q35571730 | Binding cavities and druggability of intrinsically disordered proteins |
| Q37653031 | Bioinformatical approaches to characterize intrinsically disordered/unstructured proteins |
| Q37103616 | Cell-division inhibitors: new insights for future antibiotics |
| Q34787399 | Characterization of the interactions between the nucleoprotein and the phosphoprotein of Henipavirus |
| Q39356263 | Comprehensive review of methods for prediction of intrinsic disorder and its molecular functions |
| Q87190843 | Conformational stability of PCID2 upon DSS1 binding with molecular dynamics simulation |
| Q92932799 | Conservation of Potentially Druggable Cavities in Intrinsically Disordered Proteins |
| Q27653453 | Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes |
| Q30456084 | DNdisorder: predicting protein disorder using boosting and deep networks |
| Q52593130 | Deciphering the dark proteome of Chikungunya virus. |
| Q37739405 | DisBind: A database of classified functional binding sites in disordered and structured regions of intrinsically disordered proteins |
| Q28550591 | DisPredict: A Predictor of Disordered Protein Using Optimized RBF Kernel |
| Q30376073 | Disorder-to-order conformational transitions in protein structure and its relationship to disease. |
| Q33814963 | Dr. PIAS: an integrative system for assessing the druggability of protein-protein interactions |
| Q41865629 | Drug Targeting of alpha-Synuclein Oligomerization in Synucleinopathies |
| Q35781398 | Druggability of Intrinsically Disordered Proteins |
| Q36071932 | Dynamical coupling of intrinsically disordered proteins and their hydration water: comparison with folded soluble and membrane proteins |
| Q42177256 | Dynamics of the intrinsically disordered C-terminal domain of the nipah virus nucleoprotein and interaction with the x domain of the phosphoprotein as unveiled by NMR spectroscopy |
| Q30010028 | Engineering of an elastic scaffolding polyprotein based on an SH3-binding intrinsically disordered titin PEVK module |
| Q29048164 | Evaluation of disorder predictions in CASP9 |
| Q34197530 | Expanding the proteome: disordered and alternatively folded proteins |
| Q41220497 | Exploring the binding diversity of intrinsically disordered proteins involved in one-to-many binding |
| Q37855889 | Finding order within disorder: elucidating the structure of proteins associated with neurodegenerative disease |
| Q28478955 | HelmCoP: an online resource for helminth functional genomics and drug and vaccine targets prioritization |
| Q28541113 | High-throughput screening reveals alsterpaullone, 2-cyanoethyl as a potent p27Kip1 transcriptional inhibitor |
| Q38732930 | How order and disorder within paramyxoviral nucleoproteins and phosphoproteins orchestrate the molecular interplay of transcription and replication |
| Q37951586 | How random are intrinsically disordered proteins? A small angle scattering perspective |
| Q38089151 | How to design multi-target drugs. |
| Q37557811 | Identification of a Drug Targeting an Intrinsically Disordered Protein Involved in Pancreatic Adenocarcinoma |
| Q64097123 | Identification of a novel potassium channel (GiK) as a potential drug target in : Computational descriptions of binding sites |
| Q35585498 | Identification of inhibitors of biological interactions involving intrinsically disordered proteins |
| Q41015632 | Identification of small-molecule binding pockets in the soluble monomeric form of the Aβ42 peptide |
| Q36554344 | Inherent relationships among different biophysical prediction methods for intrinsically disordered proteins |
| Q50559158 | Intrinsic Disorder and Semi-disorder Prediction by SPINE-D. |
| Q34594105 | Intrinsic disorder in scaffold proteins: getting more from less |
| Q35044139 | Intrinsic disorder mediates hepatitis C virus core-host cell protein interactions. |
| Q33514873 | Intrinsic structural disorder confers cellular viability on oncogenic fusion proteins |
| Q27926249 | Intrinsically Disordered Side of the Zika Virus Proteome |
| Q38007557 | Intrinsically disordered proteins and novel strategies for drug discovery |
| Q35510300 | Intrinsically disordered proteins in cellular signalling and regulation. |
| Q21560973 | Intrinsically unstructured domain 3 of hepatitis C Virus NS5A forms a "fuzzy complex" with VAPB-MSP domain which carries ALS-causing mutations |
| Q28534062 | Ligand clouds around protein clouds: a scenario of ligand binding with intrinsically disordered proteins |
| Q34688655 | Marked variability in the extent of protein disorder within and between viral families |
| Q28477146 | Mechanism of the interaction between the intrinsically disordered C-terminus of the pro-apoptotic ARTS protein and the Bir3 domain of XIAP |
| Q38669148 | Methods of probing the interactions between small molecules and disordered proteins |
| Q27313374 | Microsecond molecular dynamics simulations of intrinsically disordered proteins involved in the oxidative stress response |
| Q64087496 | Modulation of Disordered Proteins with a Focus on Neurodegenerative Diseases and Other Pathologies |
| Q38453820 | Molecular recognition features (MoRFs) in three domains of life |
| Q38533275 | Multiscale ensemble modeling of intrinsically disordered proteins: p53 N-terminal domain |
| Q38198240 | NMR contributions to structural dynamics studies of intrinsically disordered proteins |
| Q37891686 | Novel strategies for drug discovery based on Intrinsically Disordered Proteins (IDPs) |
| Q45965349 | POODLE-L: a two-level SVM prediction system for reliably predicting long disordered regions. |
| Q33909288 | Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases |
| Q21145360 | Prediction of protein binding regions in disordered proteins |
| Q37030888 | Privileged scaffolds targeting reverse-turn and helix recognition. |
| Q26801512 | Protein Folding and Mechanisms of Proteostasis |
| Q30456527 | Protein crystallization in drug design: towards a rational approach |
| Q37862224 | Protein-protein interactions: principles, techniques, and their potential role in new drug development |
| Q28479221 | Proteins with complex architecture as potential targets for drug design: a case study of Mycobacterium tuberculosis |
| Q33318734 | REDCRAFT: a tool for simultaneous characterization of protein backbone structure and motion from RDC data |
| Q64945196 | Recent Advances in Computational Protocols Addressing Intrinsically Disordered Proteins. |
| Q37324058 | Redefining the BH3 Death Domain as a 'Short Linear Motif'. |
| Q38218411 | Retrospective on the all-in-one retroviral nucleocapsid protein |
| Q91708289 | Sequence-Derived Markers of Drug Targets and Potentially Druggable Human Proteins |
| Q39295360 | Small molecule screening identifies regulators of the transcription factor ΔFosB |
| Q27025648 | Small-molecule inhibitors of the Myc oncoprotein |
| Q51362509 | Stochastic simulation of structural properties of natively unfolded and denatured proteins. |
| Q35902551 | Structural Disorder within Paramyxoviral Nucleoproteins and Phosphoproteins in Their Free and Bound Forms: From Predictions to Experimental Assessment |
| Q47094704 | Structural analysis of the complex between influenza B nucleoprotein and human importin-α. |
| Q33640276 | Structural disorder within Henipavirus nucleoprotein and phosphoprotein: from predictions to experimental assessment |
| Q38005681 | Structure of metabotropic glutamate receptor C-terminal domains in contact with interacting proteins |
| Q36638977 | Structure-based Inhibitor Design for the Intrinsically Disordered Protein c-Myc |
| Q36020398 | Targeting intrinsically disordered proteins in neurodegenerative and protein dysfunction diseases: another illustration of the D(2) concept |
| Q35835558 | Targeting intrinsically disordered proteins in rational drug discovery |
| Q27348831 | Targeting protein-protein interactions for parasite control |
| Q27651262 | The NMR structures of the major intermediates of the two-domain tick carboxypeptidase inhibitor reveal symmetry in its folding and unfolding pathways |
| Q56978719 | The Rational Discovery of a Tau Aggregation Inhibitor |
| Q36379177 | The conformational ensembles of α-synuclein and tau: combining single-molecule FRET and simulations |
| Q37347480 | The retinal cGMP phosphodiesterase gamma-subunit - a chameleon |
| Q42174981 | The role of intrinsically unstructured proteins in neurodegenerative diseases |
| Q38481133 | The role of structural disorder in cell cycle regulation, related clinical proteomics, disease development and drug targeting. |
| Q30372413 | The unfoldomics decade: an update on intrinsically disordered proteins. |
| Q27021480 | The universally conserved prokaryotic GTPases |
| Q38806231 | Therapeutic Interventions of Cancers Using Intrinsically Disordered Proteins as Drug Targets: c-Myc as Model System. |
| Q30385084 | Understanding protein non-folding. |
| Q30155273 | VAPC, an human endogenous inhibitor for hepatitis C virus (HCV) infection, is intrinsically unstructured but forms a "fuzzy complex" with HCV NS5B. |
| Q24567790 | pE-DB: a database of structural ensembles of intrinsically disordered and of unfolded proteins |
Search more.